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Abstract
Background: Higher Fetuin-A (FA) concentrations were found to be associated with
obesity and there is an interest to the relation between maternal FA and pregnancy
outcomes.
Objective: In this study, our aim was to evaluate the association of maternal plasma
levels of FA with fetal growth restriction (FGR).
Materials and Methods: 41 pregnant women with FGR and 40 controls were recruited
in this case-control study between July and November 2015. At the diagnosis of FGR,
venous blood samples (10 cc) were obtained for FA analysis.
Results: Maternal plasma FA levels were significantly higher in fetal growth-restricted
pregnant women compared with controls (19.3 ± 3.0 ng/ml vs 25.9 ± 6.8 ng/ml, p =
0.001). Area under receiver operating characteristic curve analysis of FA in FGR was
0.815 (95% confidence interval (CI): 0.718-0.912, p < 0.001). The maternal FA levels
with values more than 22.5 ng/ml had a sensitivity of about 73.17% (95% CI: 56.79-
85.25) and a specificity of about 82.5% (95% CI: 66.64-92.11) with positive and negative
predictive values of about 81.08% (95%CI: 64.29-91.45) and 75% (95%CI: 59.35-86.30),
respectively. Therefore, the diagnostic accuracy was obtained about 77.78%.
Conclusion: The results of this study show higher maternal plasma levels of FA in
FGR. Further studies are needed in order to demonstrate the long-term effects of FA
in pregnancies complicated with FGR and early prediction of FGR.
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1. Introduction
Fetal growth restriction (FGR) is reported in 7-15%
of all pregnancies (1), the condition is suggested
as one of the most common problems in perinatal
medicine. There are many debates about FGR,
where a universal consensus definition has yet to
be gained. American College of Obstetricians and
Gynecologists describes FGR as “fetuses with an
estimated fetal weight less than the 10th percentile
for gestational age” (2). Recently, a consensus
definition of intrauterine growth restriction was
published defining early and late FGR together
with cut-off values for the involved parameters
(3). Postnatal abnormal neurological development,
and neonatal morbidities such as polycythemia,
intraventricular bleeding, and other metabolic dis-
orders impose further importance on FGR (4-
6).
There has also been an interest in the relation
between Fetuin-A (FA) (Human fetuin-A/alpha2-
Heremans-Schmid glycoprotein) and FGR pregnan-
cies. Initially, FA levels were reported to increase
with gestational age (7). Higher FA concentrations
were found to be associated with obesity and
atherogenesis (8). Moreover, gestational diabetic
women exhibited elevated levels of FA com-
pared to pregnant women with normal glucose
metabolism (7). However, FA has been known
to regulate the function of insulin in adipocytes
and skeletal myocytes (9) and reported to involve
in the inhibition of calcification by impeding the
calcification-inducing effects of major proteins that
promote cardiac valvular calcifications (10). The
origin of its serum isoform is the hepatocytes,
and its hepatic phosphorylation decreases the
transduction of the signal of the insulin recep-
tor that may improve insulin resistance during
pregnancy (9, 11). FA was also defined as a
negative inflammatory mediator (11). In addition,
it was shown that FA significantly increased in
pregnant women with preeclampsia (12-14). More-
over, FA may predict the success of in-vitro fer-
tilization procedures (14). It has been suggested
that besides FA, insulin and insulin-like growth
factors have a role in the growth of the fetus
(15).
In this study, we aimed to evaluate the role
of maternal plasma levels of FA in pregnancies
complicated with FGR.
2. Materials and Methods
Between July and November 2015, all pregnant
women who were referred to the Perinatology
Department of tertiary referral hospital and had
the diagnosis of FGR were enrolled in the trial.
The definition of FGR was based on the estimated
fetal weight below the 10th percentile on ultra-
sound, together with birth weight below the 10th
percentile of the standard growth curve (2, 16).
Age, body mass index, gravidity, and gestational
age-matched pregnant women who were routinely
followed up were included into the control group.
Any fetus with chromosomal abnormalities, mul-
tiple pregnancies, singletons with systemic dis-
ease including hypertension (systolic and diastolic
arterial tension > 140/90 mmHg, respectively),
diabetes mellitus (according to positive 50 gr
and 100 gr oral glucose tolerance test), alcohol
users or smokers, any chronic drug users were
excluded from the study. At the diagnosis of FGR,
venous blood samples (10 cc) were obtained in
sterile conditions into ethylenediaminetetraacetic
acid red tubes. The samples were centrifuged at
4000 rpm for 10 min. The samples were stored
at -80°C until the time of analysis. Calculation of
plasma FA levels was performed by a sandwich
enzyme-based technique (BioVendor Laboratory
Medicine Inc., Brno, Czech Republic) (17). Plasma FA
concentration values were expressed as ng/ml.
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2.1. Ethical consideration
This study was conducted according to the
Declaration of Helsinki (18). The institutional review
board of the University of Health Sciences, Zekai
Tahir Burak Women’s Health Care, Education,
and Research Hospital approved the protocol
of this case-control study (28/10/2014 #26) and
all participants gave a written informed con-
sent.
2.2. Statistical analysis
IBM SPSS (Statistical Package for the Social
Sciences) Version 23 (IBM Corp., Armonk, NY,
USA) was used for the statistical analysis. The
Kolmogorov-Smirnov test was used to evaluate the
normality of the variables of the groups. Paramet-
ric data were evaluated using the independent
two-sample t-test, and non-parametric data were
compared using the Mann-Whitney U test. The
screening efficiency of FA was evaluated by the
receiver operating characteristic (ROC) analysis.
The cut-off value obtained by ROC curve anal-
ysis was employed in the measurement of sen-
sitivity, specificity, positive and negative predic-
tive values, and diagnostic accuracy. A two-tailed
p-value < 0.05 was considered statistically signifi-
cant.
3. Results
The demographic features of the participants
are depicted in Table I. There were 41 pregnant
women with FGR and 40 controls. No difference
was found between the study group and controls
in terms of age, body mass index, gravidity, parity,
and gestational week. The FGR was characterized
by lower neonatal birth weight and Apgar score at
min 5 (p < 0.001).
Maternal plasma FA levels significantly
increased in FGR group compared to controls
(19.3 ± 3.0 ng/ml vs 25.9 ± 6.8 ng/ml, p = 0.001)
(Table I). Figure 1 shows the area under ROC curve
(AUC) analysis of FA in FGR which is 0.815, (95%
confidence interval (CI): 0.718-0.912, p < 0.001).
The maternal FA levels with values more than
22.5 ng/ml had a sensitivity of about 73.17% (95%
CI: 56.79-85.25) and a specificity of about 82.5%
(95% CI: 66.64-92.11) with positive and negative
predictive values (PPV and NPV) of about 81.08%
(95% CI: 64.29-91.45) and 75% (95% CI: 59.35-
86.30), respectively. Therefore, the diagnostic
accuracy was about 77.78%.
Table I. Demographic features and the results of patients
FGR (n = 41) Control (n = 40) P-value*
Age (yr) 25.9 ± 6.0 27.2 ± 5.2 0.101
BMI (kg/m2) 28.2 ± 4.2 28.0 ± 3.2 0.765
Gravida (number) 1.9 ± 1.2 2.0 ± 1.2 0.535
Parity (number) 0.7 ± 0.9 0.7 ± 0.7 0.880
Gestational age at blood sampling (wk) 37.0 ± 2.9 36.8 ± 3.4 0.875
Birthweight (gr) 2401 ± 413 3200 ± 546 < 0.001
Apgar score at min 5 9.7 ± 0.6 8.7 ± 0.8 < 0.001
Fetuin-A level (ng/ml) 25.9 ± 6.8 19.3 ± 3.0 0.001
Umbilical Artery S/D ratio 2.4 ± 0.64 2.12 ± 0.29 0.001
Data presented as mean ± SD; Mann Whitney U test
FGR: Fetal growth restriction
BMI: Body mass index
P < 0.05 indicates significant difference
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Figure 1. The area under the receiver operating characteristic
curve for Fetuin-A in fetal growth restriction.
4. Discussion
There was no statistically significant difference
between the FGR group and the control group
in terms of age, body mass index, gravidity,
parity, and gestational age at blood sampling.
However, Fetuin-A level was found higher in
the FGR group compared to the control group.
Maternal factors as hypertensive disorders, renal
disease, smoking, alcohol use, severe nutritional
deficiencies; fetal factors as multiple gestations,
infections, aneuploidy or structural abnormalities,
and finally placental abnormalities have been
traditionally defined as the causes of FGR (19).
It is relatively straight forward to enlighten the
underlying reason of an FGR case with placental
insufficiency (by using Doppler ultrasound), aneu-
ploidy (by karyotyping), infections (by Polymerase
chain reaction analysis), and structural abnormal-
ities (by ultrasound) (2, 20). However, in some
instances, efforts regarding the etiology of FGR do
not reveal significant results. There is a tendency
to use the term “constitutionally small or small
for gestational age (SGA)” for the cases that do
not present with advanced forms of smallness
(estimated fetal weight < 3𝑟𝑑 centile, or signs
of fetoplacental Doppler adaptation, defined as
abnormal uterine artery (UtA) Doppler, and “FGR”
for the cases with the mentioned features (21).
However, the pathophysiological basis of these
clinical forms has not been truly understood, and
their associations with long-term outcome have not
been completely defined yet. In addition, recent
data reporting lower two-year neurodevelopmental
scores for full-term SGA infants (without placental
insufficiency) compared to the normal-sized babies
challenged the concept that SGA fetuses with
normal umbilical artery Doppler are “constitution-
ally small” but otherwise completely normal (22).
In the present study, we used the definition for
FGR that was suggested by the American College
of Obstetricians and Gynecologists, in which the
diagnosis is mainly performed by the estimated
fetal weight and/or birthweight percentiles. The
relationship between FA and FGR was investigated
by a limited number of trials. Briana and col-
leagues examined the circulating levels of human
FA in pregnant women and fetuses from FGR
and appropriate-for-gestational-age pregnancies.
They found that plasma FA values showed no
difference between FGR cases and appropriate-
for-gestational-age controls (23). The authors also
mentioned that maternal and fetal FA concen-
trations did not differ from each other and they
had a positive correlation that pointed at the
likelihood of passive transplacental transfer (23).
Conversely, Karamessinis and co-worker found
the post-translational modifications of the FA in
umbilical cord plasma of FGR neonates by showing
the single- and heavy-chain forms of FA that did
not contain the normally present O-linked sialic
acids. They concluded that prominent defects in
glycosylation/sialylation of FA which were shown in
their study might be the reason for the functional
impairment of FA, leading to deficient fetal growth
(24).
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In another well-designed study, Gomez and col-
leagues declared that extravillous cell viability and
invasion was reduced by FA. Moreover, elevated
plasma FA values were more frequently observed
in preeclampsia groups than control cases, even
after we controlled for diabetes mellitus, hyperten-
sion, and obesity (25).
The findings of the present study, indicating
elevated plasma FA levels in pregnancies com-
plicated by FGR, also supported the view that
high concentrations of FA ended in a reversal of
the invasiveness of extravillous trophoblast cells
that was enhanced by growth factors. Today, the
association between FA and metabolic syndrome
(understood as a disease entity) is strongly proved
(26). In addition, the rise in plasma values of FA
up to 10 times following hypoxic changes have
been reported in some animal trials, which may be
contributed by injured-cell-derived high-mobility
group box-1 protein in the expression of this sub-
stance (27, 28). It was also announced that plasma
FA levels were increased in study participants
with brain ischemic injury. The plasma FA levels
were supported positively with high levels of low-
density lipoprotein cholesterol (29, 30). In our point
of view, these common findings suggest further
investigations for the possible mutual mechanisms
- in addition to the inhibition of insulin receptor
tyrosine kinase which is the main function of FA -
for FGR and trauma, a stroke which may give extra
hint to the pathogenesis and management of FGR.
Our study has some limitations which suggest
that a more comprehensive study is needed to
draw a more concrete conclusion in terms of
FA levels in the normal population and pregnant
women with FGR, and to create percentile ranks
for gestational weeks as well. As being a negative
acute phase reactant, research of FA in relation
with other frequently used markers for inflamma-
tion may reveal the inflammation status of the
disorder (31). And finally, the detection of the
umbilical cord or neonatal plasma FA levels would
denote additional data about the issue.
5. Conclusion
The results of this study show higher maternal
plasma levels of FA in FGR. Further studies are
needed in order to demonstrate the long-term
effects of FA in pregnancies complicated with FGR
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